CASPASE 3 AS PROGNOSTIC MARKER FOR TRIPLE NEGATIVE BREAST CANCER CHEMOTHERAPY
DOI:
https://doi.org/10.22159/ajpcr.2017.v10i11.20451Keywords:
Triple negative breast cancer, Chemotherapy, Caspase, ApoptosisAbstract
Â
 Objectives: This study will examine the expression of caspase-3 and apoptotic index (AI) in triple negative breast cancer (TNBC). By knowing the non-responsiveness effect earlier, adverse effects of chemotherapy can be avoided.
Methods: This prospective cohort study has been approved by the local Ethics Committee. A total of 60 consent TNBC patients from Haji Adam Malik General Hospital and Bunda Thamrin Hospital were included in the study. Patients with heart, kidney, liver disease, history of surgery, chemotherapy, or hormonal therapy were excluded. Samples were analyzed immunohistochemically by monoclonal antibodies to assess caspase 3 and AI. Clinical chemotherapy response is determined as a positive or negative response based on Response Evaluation Criteria in Solid Tumors.
Results: The results of this study indicated that caspase 3 was increased post-chemotherapy but could not predict the clinical response of chemotherapy. Caspase-3 post-chemotherapy (5.27±1.27 pg/mL) compared to pre-chemotherapy (4.60±1.09 pg/mL) increased significantly (p=0.003) by 0.67±1.66 pg/mL but no difference was found in AI score (p=0.819). Neither caspase 3 nor the AI were associated with a clinical chemotherapy response (p=0.514 and p=0.993, subsequently).
Conclusion: Further research with larger samples is needed to determine the role and pathway of chemotherapy induced caspase 3 rise.
Downloads
References
Wu J, Li S, Jia W, Su F. Response and prognosis of taxanes and anthracyclines neoadjuvant chemotherapy in patients with triple-negative breast cancer. J Cancer Res Clin Oncol 2011;137(10):1505-10.
Ponvinobala K, Kanchana G, Rubalakshmi G. In vitro anticancer activity of hydro-alcohol extract of leaves of Andrographis neesiana aginst PC-3 and MCF-7 cell lines. Int J Pharm Pharm 2012;4(3):396-9.
Liedtke C, Mazouni C, Hess KR, Andre F, Tordai A. Response to neoadjuvant therapy and long-term survival in patients with triple-negative breast cancer. J Clin Oncol 2011;6(8):1275-81.
Fisher B, Brown A, Mamounas E, Wieand S, Robidoux A, Margolese RG, et al. Effect of preoperative chemotherapy on local-regional disease in wome with operable breast cancer: Findings from National Surgical Adjuvant Breast and Bowel Project B-18. J Clin Oncol 1997;15(7):2483-93.
Indran IR, Tufo G, Pervaiz S, Brenner C. Recent advances in apoptosis, mitochondria and drug resistance in cancer cells. Biochim Biophys
Acta 2011;1807(6):735-45.
Rakha EA, Reis-Filho JS, Baehner F, Dabbs DJ, Decker T, Eusebi V, et al. Breast cancer prognostic classification in the molecular era: The role of histological grade. Breast Cancer Res 2010;12(4):207.
Omar MS, Crowe A, Hughes J. Distribution of the single nucleotide polymorphism C3435T of MDR1 gene among people in Western Australia. Int J Pharm Pharm 2013;5(4):470-3.
Bao Q, Shi Y. Apoptosome: A platform for the activation of initiator caspases. Cell Death Differ 2007;14(1):56-65.
Rastogi R, Richa P, Sinha RP. Apoptosis: Molecular mechanisms and pathogenicity. EXCLI J 2009;8:155-81.
van der Hage JA, Mieog JS, van de Velde CJ, Putter H, Bartelink H, van de Vijver MJ. Impact of established prognostic factors and molecular subtype in very young breast cancer patients: Pooled analysis of four EORTC randomized controlled trials. Breast Cancer Res 2011;13(3):R68.
Alenzi FQ, Lotfy M, Wyse R. Swords of cell death: Caspase activation and regulation. Asian Pac J Cancer Prev 2010;11(2):271-80.
Luo M, Lu Z, Sun H, Yuan K, Zhang Q, Meng S, et al. Nuclear entry of active caspase-3 is facilitated by its p3-recognition-based specific cleavage activity. Cell Res 2010;20(2):211-22.
Surveillance Epidemiology and End Results (SEER) Program. SEER/stat database: Incidence-SEER 13 regs research data, Nov 2009 Sub (1992-2007) - Linked to county attributes - Total US 1969-2007 counties, National Cancer Institute. Cancer Stat 2010;1:1-89.
Ambrosone CB, Zirpoli G, Ruszczyk M, Shankar J, Hong CC, McIlwain D, et al. Parity and breastfeeding among African-American women: Differential effects on breast cancer risk by estrogen receptor status in the Women’s Circle of Health Study. Cancer Causes Control 2014;25(2):259-65.
Stark A, Kapke A, Schultz D, Brown R, Linden M, Raju U. Advanced stages and poorly differentiated grade are associated with an increased risk of HER2/neu positive breast carcinoma only in White women: Findings from a prospective cohort study of African-American and White-American women. Breast Cancer Res Treat 2008;107(3):405-14.
Xing P, Li J, Jin F. A case-control study of reproductive factors associated with subtypes of breast cancer in Northeast China. Med Oncol 2010;27:926-31.
Yang, HL, Chen CS, Chang WH, Lu FJ, Lai YC, Chen CC, et al. Growth inhibition and induction of apoptosis in MCF-7 breast cancer cells by antrodia camphorata. Cancer Lett 2006;231(2):215-27.
Phipps AI, Buist DS, Malone KE, Barlow WE, Porter PL, Kerlikowske K, et al. Reproductive history and risk of three breast cancer subtypes defined by three biomarkers. Cancer Causes Control 2011;22(3):399-405.
Yarso KY, Sudarsa IW, Manuaba IB. Clinical initial response of neoadjuvant chemotheraphy in triple negative, HER-2, and luminal types of breast cancer in denpasar (a preliminary study). Bali Med J 2012;1(1):12-6.
Torrisi R, Balduzzi A, Ghisini R, Rocca A, Bottiglieri L, Giovanardi F, et al. Tailored preoperative treatment of locally advanced triple negative (hormone receptor negative and HER2 negative) breast cancer with epirubicin, cisplatin, and infusional fluorouracil followed by weekly paclitaxel. Cancer Chemother Pharmacol 2008;62(4):667-72.
von Minckwitz G, Eidtmann H, Loibl S, Blohmer JU, Costa SD, Fasching PA, et al. Integrating bevacizumab, everolimus, and lapatinib into current neoadjuvant chemotherapy regimen for primary breast cancer. Safety results of the GeparQuinto trial. Ann Oncol 2011;22(2):301-6.
Salako O, Poku R, Nkembo A, Amissah F, Ntantie E, Lamango N. Treatment of triple negative breast cancer-derived cells with polyisoprenylated cysteinyl amide inhibitors activates caspase 3/7 and disrupts F-actin organization leading to apoptosis and diminished cell motility. Faseb 2016;30(1):1-3.
Devarajan E, Sahin AA, Chen JS, Krishnamurthy RR, Aggarwal N, Brun AM, et al. Down-regulation of caspase 3 in breast cancer: A possible mechanism for chemoresistance. Oncogene 2002;21(57):8843-51.
Salakou S, Kardamakis D, Tsamandas AC, Zolota V, Apostolakis E, Tzelepi V, et al. Increased Bax/Bcl-2 ratio up-regulates caspase-3 and increases apoptosis in the thymus of patients with myasthenia gravis. In Vivo 2007;21(1):123-32.
Yang XH, Sladek TL, Liu X. Reconstitution of caspase-3 sensitizes MCF-7 breast cancer cells to doxorubicin-and etoposide-induced apoptosis. Cancer Res 2001;61(1):348-54.
O’Donovan N, Crown J, Stunell H, Hill AD, McDermott E, O’Higgins N, et al. Caspase 3 in breast cancer.Clin Cancer Res 2003;9(2):738-42.
Sharma S, Hiran KR, Pavithran K, Vijaykumar DK. A pilot study to assess the feasibility of evaluation of markers of response to chemotherapy at one day & 21 days after first cycle of chemotherapy in carcinoma of breast: A prospective non-randomized observational study. World J Surg Oncol 2009 30;7:35.
Published
How to Cite
Issue
Section
The publication is licensed under CC By and is open access. Copyright is with author and allowed to retain publishing rights without restrictions.
